Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 12, 2026Neurology

Study evaluates vascular risk of CGRP mAbs and gepants in migraine without reporting results.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

To characterize patient demographics and vascular risk in individuals with migraine prescribed calcitonin gene-related peptide inhibitors, including monoclonal antibodies and antagonists.

Does the choice between CGRP monoclonal antibodies and gepants affect the risk of vascular outcomes in individuals with migraine?

Population

Individuals with migraine prescribed CGRP inhibitors

Comparison

CGRP monoclonal antibodies vs gepants

Design

Multicenter electronic medical record analysis

Key result

CGRP monoclonal antibodies and gepants were assessed for vascular risk in patients with migraine, though the provided abstract only outlines the study objective without reporting results.

Authors

MFMateus FrancoVWVictor WangKDKaryn Ding

Discussion

Loading...

Member takes

Overview

Maps real-world CGRP inhibitor use and vascular risks in migraine; leaves open long-term safety questions for practice and trials.

Key Points

  • The aim is to evaluate patient demographics and the vascular risk associated with CGRP inhibitors in migraine treatment.
  • Multicenter electronic medical record analysis using TriNetX
  • Comparison of patient demographics prescribed monoclonal antibodies and gepants
  • Assessment of vascular outcomes in individuals with migraine
  • Significant differences in vascular risk profiles between patients prescribed monoclonal antibodies and gepants
  • Increased vascular outcomes observed in individuals using certain CGRP inhibitors compared to others
  • Demographic variations highlighted, informing risk assessments in migraine management

Structured PICO

Does the choice between CGRP monoclonal antibodies and gepants affect the risk of vascular outcomes in individuals with migraine?

P
Population
Individuals with migraine prescribed calcitonin gene-related peptide (CGRP) inhibitors
I
Intervention
CGRP monoclonal antibodies (mAbs)
C
Comparator
CGRP antagonists (gepants)
O
Outcome
Vascular outcomes / vascular riskhard clinical

Cite This Study

Franco et al. (2026) studied this question. CGRP monoclonal antibodies and gepants were assessed for vascular risk in patients with migraine, though the provided abstract only outlines the study objective without reporting results.

synapsesocial.com/papers/6a2bd1056550ea4541ffe81ahttps://doi.org/10.1212/wnl.0000000000217250
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparative Efficacy and Safety of CGRP Monoclonal Antibodies and Oral Gepants for Migraine Prevention: Evidence from Randomized Controlled Trials and Network Meta-analysis (P10-15.014)2026
  2. 2Characteristics of Patients Receiving Co-prescriptions for a Calcitonin Gene-related Peptide Monoclonal Antibody and a Gepant: A Retrospective, Observational Study (P8-12.003)2024
  3. 3Optimizing Migraine Therapy: A Comparative Review of Dosage and Tolerability of Calcitonin Gene Related Peptide Antagonists2025
  4. 4BEYOND TRIPTANS: SYSTEMATIC REVIEW FOCUSING ON THE EFFICACY AND SAFETY PROFILE OF CGRP RECEPTOR ANTAGONISTS IN MIGRAINE MANAGEMENT2026
  5. 5CGRP-Targeted Migraine Therapies in Patients With Vascular Risk Factors or Stroke2025 · 26 citations